- Home
- JANX vs LXRX Comparison
JANX vs LXRX Comparison
Compare JANX & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JANX | LXRX |
|---|---|---|
| Founded | 2017 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 996.7M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | JANX | LXRX |
|---|---|---|
| Price | $17.54 | $1.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 6 |
| Target Price | ★ $33.81 | $4.47 |
| AVG Volume (30 Days) | 751.0K | ★ 1.8M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | N/A | ★ N/A |
| Revenue | $10,000,000.00 | ★ $49,803,000.00 |
| Revenue This Year | $194.24 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $12.12 | $1.10 |
| 52 Week High | $35.34 | $2.68 |
Technical Indicators
Market Signals| Indicator | JANX | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.36 | 29.09 |
| Support Level | $15.90 | $1.39 |
| Resistance Level | $19.16 | $2.49 |
| Average True Range (ATR) | 0.83 | 0.09 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 48.72 | 17.46 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.